This study will evaluate the safety and efficacy of NKTR-255 following CD19-directed chimeric antigen (CAR)-T cell therapy in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). NKTR-255 is an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. T cells are infection fighting blood cells that can kill tumor cells. Chimeric antigen (CAR)-T cell product consists of genetically engineered T-cells, modified to recognize CD19, a protein on the surface of cancer cells. These CD19-specific T cells may help the body's immune system identify and kill CD19-positive cancer cells. Giving NKTR-255 following the treatment with CD19 CAR-T cell therapy may work better in treating large B-cell lymphoma than either drug alone.
2 Primary · 9 Secondary · Reporting Duration: Up to 3 years
400 Total Participants · 4 Treatment Groups
Primary Treatment: Stage 1 NKTR-255 at 3.0 μg/kg · Has Placebo Group · Phase 2 & 3
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: